Skip to content

Efficacy and Safety of a Combination of Emotional Freedom Technique with Acupuncture versus Acupuncture Alone to Treat Psychiatric Symptoms in Parkinson’s disease A protocol for a randomized, assessor-blind, parallel-group clinical trial

Efficacy and Safety of a Combination of Emotional Freedom Technique with Acupuncture versus Acupuncture Alone to Treat Psychiatric Symptoms in Parkinson’s disease A protocol for a randomized, assessor-blind, parallel-group clinical trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0005964
Enrollment
80
Registered
2021-03-05
Start date
2021-09-06
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others : EFT combined with Acupuncture -EFT: Once a week. (12 times during 12 weeks) -Acupuncture: Twice a week. (24 times during 12 weeks)

Sponsors

Daejeon Korean Medicine Hospital of Daejeon University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Aged 45 to 85 2) Diagnosed with Parkinson's disease 3) Hoehn and Yahr Scale 1-3 4) The 15-item Geriatric Depression Scale(GDS-15) over 6 5) Participants who voluntarily decided to participate and signed the consent form 6) Mini Mental State Examination-K(MMSE-K) over 24

Exclusion criteria

Exclusion criteria: 1) Patients with dementia, Huntington's disease, or hydrocephalus 2) Patients with gait disturbance due to cerebral vascular accidents, brain tumor, or other cerebral diseases 3. Participants who have taken or changed the dosage of anti-Parkinsonism medications, materials, or medications that may affect depression(Ex. anti-anxiolytic drugs, anti-depressive drugs, anti-psychotic drugs, steroids, female hormones, L-dopa, Digitalis, bromide, cyclosporin, disulfiram, isoniazid, yohimbine), in recent 4 weeks 4) Not appropriate to participate in the trial due to the lab test results(Ex. over 2 times the upper reference limit of AST, ALT, T bilirubin, or creatinine) 5) Seriously unstable medical conditions (the investigator will decide based on Vital signs, EKG, and Chest PA by SOP. Ex. active TB on Chest PA, or signs of ventricular fibrillation or myocardial infarctions on EKG) 6) Participants who have been treated by Korean medical treatment related to Parkinson's disease in recent 2 weeks, that the treatment may affect this trial or the safety. 7) Pregnant or lactating women 8) Participants who are thought to be not appropriate to participate in this trial by the investigator.

Design outcomes

Primary

MeasureTime frame
Beck Depression Inventory (BDI)

Secondary

MeasureTime frame
Amount of execise;Beck Depression Inventory (BDI);Parkinson’s disease Sleep Scale (PDSS);State-Trait Anxiety Inventory(STAI);K-FRAIL scale;UPDRS ?;Functional near-infrared spectroscopy (fNIRS)

Countries

Korea, Republic of

Contacts

Public ContactDong-Hoon Kang

Daejeon Korean Medicine Hospital of Daejeon University

eastking@kakao.com+82-42-470-9561

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026